Medivir マネジメント

マネジメント基準チェック /14

Medivirの CEO はJens Lindbergで、 Jan2022年に任命され、の在任期間は 2.83年です。の年間総報酬はSEK 7.82Mで、 32.8%給与と67.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.15%を直接所有しており、その価値はSEK 482.62K 。経営陣と取締役会の平均在任期間はそれぞれ4年と1.3年です。

主要情報

Jens Lindberg

最高経営責任者

SEK 7.8m

報酬総額

CEO給与比率	32.8%
CEO在任期間	2.8yrs
CEOの所有権	0.1%
経営陣の平均在職期間	4yrs
取締役会の平均在任期間	1.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Medivir の収益と比較して、Jens Lindberg の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-SEK 106m
Mar 31 2024	n/a	n/a	-SEK 97m
Dec 31 2023	SEK 8m	SEK 3m	-SEK 89m
Sep 30 2023	n/a	n/a	-SEK 87m
Jun 30 2023	n/a	n/a	-SEK 78m
Mar 31 2023	n/a	n/a	-SEK 75m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 89m

報酬と市場: Jensの総報酬 ($USD 731.37K ) は、 Swedish市場 ($USD 243.31K ) の同規模の企業の平均を上回っています。

報酬と収益: Jensの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Jens Lindberg (53 yo)

2.8yrs

在職期間

SEK 7,824,000

報酬

Mr. Jens Lindberg serves as Independent Director of BrainCool AB (publ) from June 26, 2024. He serves as Chief Executive Officer at Medivir AB (publ) since January 24, 2022. He served as Acting Chief Execu...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jens Lindberg	Chief Executive Officer	2.8yrs	SEK 7.82m	0.15% SEK 482.6k
Magnus Christensen	Chief Financial Officer	5.3yrs	SEK 2.66m	0.081% SEK 263.0k
Fredrik Öberg	Chief Scientific Officer	5.2yrs	データなし	0.11% SEK 358.1k
Pia Baumann	Chief Medical Officer	1.8yrs	データなし	0.086% SEK 277.5k
Karin Tunblad	Senior Principal Scientist & MIV-818 Project Leader	no data	データなし	データなし

4.0yrs

平均在職期間

55.5yo

平均年齢

経験豊富な経営陣: MVIRの経営陣は経験豊富であると考えられます ( 4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Lennart Hansson	Independent Director	6.5yrs	SEK 260.00k	0.036% SEK 115.6k
Uli Hacksell	Chairman of the Board	6.5yrs	SEK 690.00k	0.89% SEK 2.9m
Yilmaz Mahshid	Director	3.5yrs	SEK 260.00k	0.045% SEK 144.5k
Jeong-Woo Heo	Member of Scientific Advisory Council	1.3yrs	データなし	データなし
Bengt Westermark	Independent Director	7.5yrs	SEK 260.00k	0.029% SEK 92.5k
Jeffrey Evans	Member of Scientific Advisory Council	1.3yrs	データなし	データなし
Richard Finn	Member of Scientific Advisory Council	1.3yrs	データなし	データなし
Maria Reig	Member of Scientific Advisory Council	1.3yrs	データなし	データなし
Arndt Vogel	Member of Scientific Advisory Council	1.3yrs	データなし	データなし
Anna Torner	Director	less than a year	データなし	データなし
Angelica Loskog	Director	less than a year	データなし	データなし

1.3yrs

平均在職期間

74yo

平均年齢

経験豊富なボード: MVIRの取締役会は経験豊富ではない ( 1.3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Medivir マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Medivir AB (Publ) Appoints Nomination Committee

Chief Executive Officer recently bought kr176k worth of stock

Medivir Aktiebolag (publ) Approves Board Appointments

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

High number of new and inexperienced directors

Recent updates

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

New minor risk - Share price stability

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

New major risk - Financial position

Consensus EPS estimates fall by 45%

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Chief Executive Officer recently bought kr176k worth of stock

Medivir Aktiebolag (publ) Approves Board Appointments

Consensus revenue estimates increase by 21%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 90%

Price target decreased by 8.2% to kr22.49

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

New major risk - Shareholder dilution

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Price target decreased by 16% to kr23.39

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 78%

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Share price stability

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

High number of new and inexperienced directors

Consensus revenue estimates increase by 47%, EPS downgraded

Independent Chairman of the Board recently bought kr374k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Medivir AB Announces Patent Application for Fostrox Approval in China

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Chief Executive Officer recently bought kr209k worth of stock

Price target increased by 14% to kr28.08

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 16%, revenue upgraded

Price target increased by 13% to kr27.96

Forecast to breakeven in 2024

Less than half of directors are independent

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

マネジメント基準チェック /14